Publication:
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.

Placeholder

Organizational Units

Program

Authors

UYGUN, K
BILICI, A
KAYA, S
Oven, Ustaalioglu
YILDIZ, R
TEMIZ, S
Seker, MESUT
AKSU, G
CABUK, D
GUMUS, M

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source:

Keywords:

Keywords

Citation

UYGUN K., BILICI A., KAYA S., Oven U., YILDIZ R., TEMIZ S., Seker M., AKSU G., CABUK D., GUMUS M., -XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.-, Asian Pacific journal of cancer prevention : APJCP, cilt.14, ss.2283-8, 2013

Collections

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details


Sustainable Development Goals

Thumbnail Image
Goal